Literature DB >> 20191519

Clinical course and prognostic value of disease activity in the first two years in different subtypes of juvenile idiopathic arthritis.

H M Albers1, D M C Brinkman, S S M Kamphuis, L W A van Suijlekom-Smit, M A J van Rossum, E P A H Hoppenreijs, H J Girschick, C Wouters, R K Saurenmann, J J Houwing-Duistermaat, T W J Huizinga, M W Schilham, R ten Cate.   

Abstract

OBJECTIVE: Juvenile idiopathic arthritis (JIA) is a heterogeneous disease involving chronic arthritis. The clinical course is characterized by a fluctuating pattern of active and inactive disease. We have described in detail the clinical course in different JIA subtypes during the first 2 years after diagnosis and studied its relationship to disease activity in the following years.
METHODS: Detailed clinical data on different parameters describing the disease activity in sequential time periods covering the first 2 years after diagnosis were retrieved from the charts of 311 patients with JIA and compared between subtypes. In a cohort of 146 patients, the relation of these different clinical variables to the course of disease in the following 3 years was evaluated.
RESULTS: The percentage of time with active disease in the first 2 years differed significantly between subtypes. In all subtypes, a broad spectrum of activity was observed. The time with active disease in the first 2 years was the most significant factor associated with the duration of active disease in the following years.
CONCLUSION: Different percentages of time with active disease have been observed between JIA subtypes in the first 2 years. The cumulative duration of activity varied widely within each subtype. Regarding the prognosis of the individual patient, the clinical course in the first 2 years appears to be predictive of the clinical course in the following years. Patients that have less time with active disease in the first 2 years are not likely to develop an unremitting clinical course later on.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20191519     DOI: 10.1002/acr.20069

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  11 in total

Review 1.  Defining juvenile idiopathic arthritis remission and optimum time for disease-modifying anti-rheumatic drug withdrawal: why we need a consensus.

Authors:  Thomas Broughton; Kate Armon
Journal:  Paediatr Drugs       Date:  2012-02-01       Impact factor: 3.022

2.  Remission rate is not dependent on the presence of antinuclear antibodies in juvenile idiopathic arthritis.

Authors:  M Glerup; T Herlin; M Twilt
Journal:  Clin Rheumatol       Date:  2017-01-17       Impact factor: 2.980

3.  Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis.

Authors:  Carol A Wallace; Edward H Giannini; Steven J Spalding; Philip J Hashkes; Kathleen M O'Neil; Andrew S Zeft; Ilona S Szer; Sarah Ringold; Hermine I Brunner; Laura E Schanberg; Robert P Sundel; Diana Milojevic; Marilynn G Punaro; Peter Chira; Beth S Gottlieb; Gloria C Higgins; Norman T Ilowite; Yukiko Kimura; Stephanie Hamilton; Anne Johnson; Bin Huang; Daniel J Lovell
Journal:  Arthritis Rheum       Date:  2011-12-19

4.  Frequency of joint involvement in juvenile idiopathic arthritis during a 5-year follow-up of newly diagnosed patients: implications for MR imaging as outcome measure.

Authors:  Robert Hemke; Charlotte M Nusman; Désirée M F M van der Heijde; Andrea S Doria; Taco W Kuijpers; Mario Maas; Marion A J van Rossum
Journal:  Rheumatol Int       Date:  2014-08-14       Impact factor: 2.631

5.  Attainment of inactive disease status following initiation of TNF-α inhibitor therapy for juvenile idiopathic arthritis: enthesitis-related arthritis predicts persistent active disease.

Authors:  Katherine J Donnithorne; Randy Q Cron; Timothy Beukelman
Journal:  J Rheumatol       Date:  2011-11-15       Impact factor: 4.666

6.  Clinical remission and subsequent relapse in patients with juvenile idiopathic arthritis: predictive factors according to therapeutic approach.

Authors:  Mireia Castillo-Vilella; Nuria Giménez; Jose Luis Tandaipan; Salvador Quintana; Consuelo Modesto
Journal:  Pediatr Rheumatol Online J       Date:  2021-08-21       Impact factor: 3.054

Review 7.  Clinical Outcome and Long-term Remission in JIA.

Authors:  Mia Glerup; T Herlin; M Twilt
Journal:  Curr Rheumatol Rep       Date:  2017-11-04       Impact factor: 4.592

8.  The majority of newly diagnosed patients with juvenile idiopathic arthritis reach an inactive disease state within the first year of specialised care: data from a German inception cohort.

Authors:  Claudia Sengler; Jens Klotsche; Martina Niewerth; Ina Liedmann; Dirk Föll; Arnd Heiligenhaus; Gerd Ganser; Gerd Horneff; Johannes-Peter Haas; Kirsten Minden
Journal:  RMD Open       Date:  2015-12-08

9.  A comparison of three treatment strategies in recent onset non-systemic Juvenile Idiopathic Arthritis: initial 3-months results of the BeSt for Kids-study.

Authors:  P C E Hissink Muller; D M C Brinkman; D Schonenberg; Y Koopman-Keemink; I C J Brederije; W P Bekkering; T W Kuijpers; M A J van Rossum; L W A van Suijlekom-Smit; J M van den Berg; C F Allaart; R Ten Cate
Journal:  Pediatr Rheumatol Online J       Date:  2017-02-06       Impact factor: 3.054

10.  Anti-carbamylated protein antibodies in rheumatoid arthritis patients and their association with rheumatoid factor.

Authors:  Maizatul A Othman; Wan Syamimee W Ghazali; Wan Zuraida W A Hamid; Kah K Wong; Nurul K Yahya
Journal:  Saudi Med J       Date:  2017-09       Impact factor: 1.484

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.